Old Web
English
Sign In
Acemap
>
authorDetail
>
H. Dials
H. Dials
Medicine
Pathology
in patient
Cancer
Pharmacology
4
Papers
117
Citations
0.02
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase 1 dose-escalation study of 17-allylamino-17-demethoxygeldanamycin (17AAG) in combination with irinotecan in patients with solid tumors
2016
Journal of Clinical Oncology
Archie Tse
Richard D. Carvajal
Minita Shah
H. Dials
M Fogel
Eileen M. O’Reilly
K. Y. Chung
Robert G. Maki
Nian Wu
Merrill J. Egorin
Gary K. Schwartz
Show All
Source
Cite
Save
Citations (0)
A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors
2009
Journal of Clinical Oncology
Gary K. Schwartz
S Robertson
A Shen
E W Wang
L. Pace
H. Dials
D. S. Mendelson
P. Shannon
Michael S. Gordon
Show All
Source
Cite
Save
Citations (92)
A phase I dose escalation trial of a daily oral CDK 4/6 inhibitor PD-0332991
2007
Journal of Clinical Oncology
P. J. O'Dwyer
Patricia LoRusso
Angela DeMichele
V. Gupta
A. Barbi
H. Dials
Isan Chen
R.D Courtney
Keith D. Wilner
Gary K. Schwartz
Show All
Source
Cite
Save
Citations (18)
A phase I clinical study of safingol followed by cisplatin: promising activity in refractory adrenocortical cancer with novel pharmacology
2006
Journal of Clinical Oncology
Richard D. Carvajal
Alfred H. Merrill
H. Dials
A. Barbi
G.K. Schwartz
Show All
Source
Cite
Save
Citations (7)
1